CBD Vida, a startup based in Campinas, São Paulo, Brazil has become the first company with administrative headquarters in Brazil to market cannabidiol-based drugs with direct import through prescription and medical report.
The Brazilian national market for CBD is expected to turnover $4.7 billion in the next three years, according to researchers from BDS Analytics and Arcview Market Research.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more!
Currently, 7,000 people are authorized by the Brazilian Health Regulatory Agency (ANVISA), an agency linked to the Ministry of Health, to import this type of medicine in Brazil.
For the company's CEO, Fabio Camata Candello, the moment is to invest in the Brazilian market.
"We are witnessing an expanding market and the business possibilities in CBD in Brazil are enormous. CBD Vida is a pioneer and we have a very important role in Brazilian society in providing high quality products," he said.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.